Quantum
Quanome Agrees to Invest in AI Drug Discovery Company QAI Labs
Publication: The Quantum Insider
Author: Mohib Ur Rehman
Source published: 09/11/2026, 14:42:43 UTC
Briefing created: 10/11/2026, 07:59:28 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 09/11/2026, 15:49:26 UTC.
Briefings
Quanome Technologies agreed to acquire a 5% stake in QAI Labs via an all-stock transaction, issuing 6.54 million shares to the company in exchange for approximately 15.97% of its post-transaction outstanding stock. The investment supports Quanome's Quantum Life Sciences strategy and focuses on the NOVA-3 platform, which combines AI-based antibody selection with quantum algorithms running on classical simulators. QAI Labs is located in Sugar Land, Texas, and operates at an early pre-commercial stage where candidates require laboratory validation before clinical development.
Key points
- Quanome Technologies acquired a 5% stake in QAI Labs through an all-stock transaction, issuing 6,541,236 shares to the company in exchange for approximately 15.97% of its post-transaction outstanding stock.
- QAI Labs operates in Sugar Land, Texas, and its NOVA-3 platform uses AI to select antibody candidates before laboratory work begins, though candidates remain at an early pre-commercial stage requiring validation.
Context
This investment agreement, dated November 4, 2026, represents Quanome's entry into its Quantum Life Sciences strategy. The transaction value is approximately $5 million, with an implied equity valuation of around $100 million for QAI Labs. The investment aims to accelerate the evaluation of NOVA-3 candidates using quantum-enhanced methods on classical simulators.
Limitations
The evidence covers a specific investment agreement dated November 4, 2026, with closing conditions subject to customary terms. QAI Labs remains at an early pre-commercial stage, and the transaction does not involve a subsidiary relationship. The source does not provide details on future commercialization timelines, regulatory approval status, or specific clinical trial outcomes.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 10/11/2026, 07:59:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiajw66tg3vccsz2qocpq225plyzogl4k7yb5lhsdtxvs373e7i2dq